1. Medtech Insight
  2. >>Geography
  3. >>Latin America

For Some Companies, Puerto Rico Financial Impact Uncertain

 
• By Elizabeth Orr

Lantheus Holdings, Becton Dickinson are among manufacturers to say in recent financial reports that the hurricane has ongoing impacts for the companies.

Gerald Herbert/AP
Damage from Hurricane Maria in Toa Alta, Puerto Rico • Source: Gerald Herbert/Associated Press (Gerald Herbert/AP)

While Hurricane Maria hit Puerto Rico six weeks ago, its full financial impact is yet to be felt by some device manufacturers, according to quarterly earnings reports from companies over the past week.

For example, medical imaging agent company Lantheus Holdings Inc. isn’t sure when, or if, it will fully recover. In a Nov. 2 financial filing, the company explained that its San Juan radiopharmacy – one of two on the island – was damaged in the hurricane, and the number of diagnostic imaging procedures performed since the hurricane has severely declined

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Latin America

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 
• By Brian Bossetta

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

China Strikes Back After Trump Ups Tariffs; Administration Further Delays Tariffs On Canada And Mexico

 
• By Brian Bossetta

In response to the Trump administration increasing its tariffs on imports from China, Beijing announced a ban on gene sequencers from US biotech firm Illumina, signaling a full-blown trade war could be in the making. Trump also pushed the deadline for implementing tariffs on Canada and Mexico back by another month.

PathAI Enters South American Market Partnering With Integrated Healthcare Network Rede D’or

 
• By Natasha Barrow

PathAI, a Boston-based AI-pathology startup backed by $355m, partners with Brazil’s largest integrated healthcare network to support diagnosis and treatment of cancer patients using its AISight image management system.

Could A Wider Trade War Be Brewing? Beijing Retaliates With Own Tariffs While AdvaMed Asks Administration For Exemption

 
• By Brian Bossetta

Concerns President Trump’s tariffs could create a full-blown trade war with China jumped dramatically as Beijing responded with its own set of tariffs targeting various US goods. On the medtech front, AdvaMed wants Trump to create a carve-out for Chinese medical devices as he did in his first term.

More from Geography

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 
• By Amanda Maxwell

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

UK Medtech Regulators Must Ensure Certainty So Businesses Can Plan Their Futures

 
• By Ashley Yeo

With medtech businesses typically managing investment cycles on a three- to five-year basis, local regulatory processes and forward costs of market entry must offer an attractive environment in which companies can plan for growth, says McDermott Will and Emery’s partner and head of healthcare and life sciences, Sharon Lamb. Broad-scale improvements to NICE’s evaluation offerings would similarly enhance the UK’s value to innovators.